Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients

Trial Profile

An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Pegunigalsidase alfa (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 09 Jan 2018 Status changed from recruiting to completed.
    • 03 Jan 2018 Argentina, Chile, Germany, Israel and Serbia were the planned locations as per results published in European Clinical Trials Database record.
    • 13 Feb 2017 Results from one-year follow up of patients will be presented at the 13th Annual WORLDSymposium 2017, according to a Protalix Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top